RecipientAmount (million)Deal/Technology HighlightLead InvestorsDeal TypeCountry
Arrowhead Pharmaceuticals$3,700Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. The transactions have a combined potential value of over $3.7 billion for Arrowhead.Janssen PharmaceuticalsLicensing AgreementUnited States
Endocyte$2,100Acquisition would add 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA), present in the majority of patients with mCRPC, and has shown promising Phase II data.NovartisAcquisitionUnited States
Tango Therapeutics$1,700Tango Therapeutics will be responsible for target discovery and validation under the multi-year partnership. Gilead will hold the option to claim global rights for up to five targets resulting from Tango’s functional genomics-based discovery platform.Gilead SciencesCollaborationUnited States
Publicis Media$1,500GSK Consumer Healthcare VP and Global Head of Media Scott Grenz commented: “We ran a very thorough and competitive pitch process with strong presentations from all companies, but ultimately Publicis was the best fit for us. We’re excited about the new partnership and the potential of the platform GSK model as we continue to progress our marketing transformation program.”GlaxoSmithKlineContract AgreementFrance
SQZ Biotechnologies$1,000The expanded partnership furthers the synergistic combination of SQZ's expertise in cell therapy with Roche's cancer immunotherapy expertise. SQZ and Roche will jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications.RocheExpansion of PartnershipUnited States
AstraZeneca$922Nexium, a proton pump inhibitor developed by AstraZeneca, helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers.Grünenthal GmBHDivestmentUnited Kingdom
Ionis Pharmaceuticals$760This new agreement builds upon our productive relationship with Roche on IONIS-HTTRx (RG6042), an antisense drug for the treatment of people with Huntington's disease," said Brett P. Monia, chief operating officer at Ionis. "Our antisense technology is the first to demonstrate robust, dose-dependent and sustained reduction of FB in a clinical study.RocheCollaborationUnited States
Dragonfly Therapeutics $695The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly's TriNKET™ technology platform for a number of solid-tumor programs, with the potential to earn Dragonfly up to $695 million in up front and milestone payments per program as well as royalties on sales of approved products.MerckLicensing AgreementUnited States
Kraft Heinz Co.$625“The sale of this niche business fits into our overall global growth strategy and our focus on investing in and growing brands within our core categories,” said Bernardo Hees, Chief Executive Officer of Kraft Heinz.Zydus CadilaBrand AcquisitionUnited States
Dicerna Pharmaceuticals$550The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets, along with collaborating to move beyond the current technical paradigm in order to generate next-generation oligonucleotide therapeutic agents.Eli Lilly CollaborationUnited States
Zymeworks$480LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, while Zymeworks retains rights to develop antibodies in all other therapeutic areas.LEO Pharma A/SLicensing AgreementCanada
Innovent Biologics$421The IPO attracted 10 cornerstone investors, including Sequoia Capital, Capital Group Cos. and Temasek, that agreed to buy a total of about $245 million of stock, the terms show.Sequoia CapitalIPOChina
Forbion (Forbion IV)$410Forbion IV will target substantial initial stakes, looking to take lead positions and work alongside entrepreneurial management teams to deliver exceptional financial and societal returns. Forbion has already had considerable success with this strategy via its first three funds, with the EUR 183 million Forbion III already delivering 4 exits including the sale of Rigontec to MSD and the highly successful IPO of Replimune on NASDAQ in July 2018.UndisclosedInvestmentThe Netherlands
Cerevel Therapeutics$350Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction.Bain Capital, PfizerLaunchUnited States
GW Pharmaceuticals$345GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase I and Phase II trials for epilepsy, glioblastoma, autism spectrum disorder and schizophrenia.Goldman SachsIPOUnited Kingdom
Allogene Therapeutics$324Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T(AlloCAR T™) therapies for cancer, today announced the pricing of its initial public offering of 18,000,000 shares of its common stock at a price to the public of $18.00 per share. Goldman Sachs & Co. LLCIPOUnited States
Center for Multimodality Clinical Trial Materials, Center for Active Ingredient for Biopharmaceuticals$257Astellas currently has multiple development programs utilizing these approaches at the clinical and pre-clinical stage. Therefore, with a view to the future progress of development and commercialization of these programs, Astellas has decided to construct R&D facilities in Japan and overseas for the manufacture of clinical trial materials and the initial commercial production of these products.Astellas PharmaManufacturing InvestmentJapan
Taiho Ventures$250The increase in the investment pool illustrates Taiho Ventures' strong commitment to its continuous support of innovative biotech start-ups pursuing cutting-edge drug discovery activities based on state-of-the-art science. Taiho Pharmaceutical also aims to accelerate its open innovation through these investment efforts.Taiho PharmaceuticalInvestmentJapan
Dicerna Pharmaceuticals$247“This collaboration provides the opportunity to continue building on our more than two decades of complement expertise using Dicerna’s proprietary GalXC RNAi technology platform, which provides a potentially promising new way of inhibiting the uncontrolled complement activation that we know plays a significant role in many devastating diseases.”Alexion PharmaceuticalsCollaborationUnited States
Innate Pharma$245AZ will obtain full oncology rights to the first-in-class humanised anti-NKG2A antibody, monalizumab, expanding its partnership with Innate. AZ also gains option rights to IPH5201, an antibody targeting CD39, as well as four preclinical molecules from Innate’s pipeline. Innate is licensing the US and EU commercial rights to recently FDA-approved Lumoxiti (moxetumomab pasudotox) for hairy cell leukaemia.AstraZeneca9.8% Equity StakeFrance
Galapagos NV $200AbbVie's research program aims to develop a best-in-class, triple-combination therapy for patients living with cystic fibrosis. AbbVie CollaborationSwitzerland
Orchard Therapeutics$200The biotech that specializes in ex vivo gene therapies sold 14.3 million shares to raise $200.2 million.J.P. MorganIPOUnited Kingdom
GO Therapeutics$195"GO's glycoprotein targeting platform opens an exciting class of tumor-specific antigens that can help widen the therapeutic window for cancer therapies such as T-cell bispecific antibodies, CAR-T and ADCs (Antibody Drug Conjugates). Preclinical data show GO’s approach can provide superior specificity in targeting solid tumors over normal tissue, and demonstrate clean in-vivo toxicity profiles in the context of potent immunotherapies."F. Hoffmann-La Roche LtdLicensing AgreementUnited States
Rigel Pharmaceuticals$180Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries. Rigel to receive product transfer price payments in the mid to upper twenty percent range based on tiered net sales for exclusive supply of TAVALISSEKissei PharmaceuticalLicensing AgreementUnited States
Verastem Oncology$145COPIKTRA also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.Lazard Frères & Co. LLCIPOUnited States
SI-BONE$140SI-BONE is a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®UndisclosedIPOUnited States
Axonics Modulation Technologies$138Axonics has developed an innovative rechargeable SNM system for the treatment of patients with OAB, FI, and UR. BofA Merrill LynchIPOUnited States
Lysogene$128Lysogene intends to apply the funds raised for general corporate purposes including the further development of LYS-GM101 for GM1 gangliosidosis.Sarepta TherapeuticsLicensing AgreementFrance
China Everbright Limited$115China Everbright Limited has held its first close for its Everbright Medical Healthcare Fund III at CNY 800 million ($115.2 million, €100.6 million). The fund will target investments in biotechnology and healthcare services in China.UndisclosedFundraisingHong Kong
Kala Pharmaceuticals$110“We expect this financing to support Kala’s efforts to achieve significant milestones, including the NDA filing for KPI-121 0.25% for dry eye disease by the end of 2018, the launch of INVELTYS in early 2019, and topline results for the STRIDE-3 trial of KPI-121 0.25% expected in Q4 2019.”Athyrium Capital Management, LPFinancingUnited States
Synthego$110The new funds further Synthego's mission to accelerate CRISPR capabilities for rapid and precise genome engineering in applications such as cell and gene therapies.Founders FundSeries C FinancingUnited States
Aclaris Therapeutics$107Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses, common warts, alopecia areata, and vitiligo.Leerink PartnersIPOUnited States
Infection Research$100The Infection Research Initiative is a comprehensive approach to improve outcomes associated with infections through enhanced detection, diagnosis, prevention, and treatment.Cystic Fibrosis FoundationResearch InvestmentUnited States
Morphic Therapeutic$100Both the companies have entered into a research and development collaboration designed to advance a number of Morphic's oral integrin therapeutics for fibrosis-related indications.AbbVieCollaborationUnited States
Berkeley Lights$95Berkeley Lights’ Beacon® digital cell biology platform is becoming a proven asset for the world’s top biopharmaceutical companies working in large molecule drug discovery and development.Sequoia CapitalInvestmentUnited States
Genomatica$90"Genomatica has delivered high-volume bio-based chemicals to market at costs competitive with petrochemical production, not just once but multiple times," said Jason Kelly, CEO of Ginkgo Bioworks.Casdin CapitalInvestmentUnited States
Stoke Therapeutics$90Stoke has identified thousands of genes that could be addressed by its proprietary TANGO technology, which targets non-productive RNA splicing to increase gene expression and address the root cause of monogenic diseases caused by loss or reduction of gene function.RTW InvestmentsSeries B FinancingUnited States
Kodiak Sciences$90Kodiak Sciences Inc. is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases.Morgan Stanley & Co.IPOUnited States
Vaccines Launch Facility$82The new facility in Leiden, the Netherlands has been built by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.Janssen Vaccines & Prevention B.V. Manufacturing Facility LaunchThe Netherlands
LogicBio Therapeutics$81GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression.Arix BioscienceIPOUnited States
TP Therapeutics$80TP Therapeutics will use the proceeds to advance its lead product candidate, Repotrectinib (TPX-0005), into a Phase 2 potential registration study in early 2019 for ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors.Foresite Capital, venBio PartnersMezzanine FinancingUnited States
Terns Pharmaceutical$80Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced the closing of an $80 million Series B financing.Vivo CapitalSeries B FinancingChina
Milestone Pharmaceuticals $80Etripamil is a new, potent, short-acting, investigational calcium channel blocker being developed as a rapid-onset nasal spray that can be self-administered by the patient to potentially terminate PSVT episodes whenever and wherever they may occur.Venrock Healthcare Capital PartnersPrivate FinancingCanada
NGM Biopharmaceuticals$75Its lead drug, a once-daily injectable called NGM-282, is an engineered variant of the human hormone FGF19 and will enter a mid-stage trial in first-quarter 2019.UndisclosedIPOUnited States
Proteostasis Therapeutics$74Proteostasis intends to use the net proceeds from the proposed offering to fund critical path activities for PTI-428 as an add on to standard of care and continue the advancement of PTI-proprietary combination therapies, for drug substance (API) for Phase 3 for PTI-428, PTI-801 and PTI-808. Leerink PartnersIPOUnited States
Castle Creek Pharma$72Castle Creek plans to use this additional funding to support the late-stage development of an investigational drug, diacerein ointment (CCP-020).Fidelity ManagementInvestmentUnited States
Montrose Production Facility$70Active pharmaceutical ingredients (APIs) for use in GSK’s Ellipta respiratory inhalers will be produced in the building which is the second multi-million investment in the Montrose site over the last two years.GlaxoSmithKlineManufacturing InvestmentScotland
Oxford Nanopore Technologies$66The investment in Oxford Nanopore aligns with Amgen's strategic focus on using human genetics to deliver new medicines to patients. Nanopore technology is uniquely scalable. MinIONTM, the only pocket-sized sequencer, can be used to sequence in any location. In addition, Oxford Nanopore has developed benchtop, on-demand, high-throughput devices such as PromethIONTM.AmgenEquity InvestmentUnited Kingdom
Equillium$65Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation.JefferiesIPOUnited States
University of North Carolina at Chapel Hill$65Pinnacle Hill will focus on drug research projects that are approved and directed by a joint steering committee comprised of members from UNC-Chapel Hill and Deerfield leadership teams. Each selected project has the potential to receive funding to support investigational new drug enabling studies.Deerfield ManagementPartnershipUnited States
Allergan$65The acquisition includes an exclusive license to certain intellectual property for RHOFADE, which is approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.Aclaris TherapeuticsProduct AcquisitionIreland
Merck KGaA$63Luminex will own the flow cytometry platforms Amnis® and Guava® and the associated reagents under those brands. Merck continues to actively manage its comprehensive portfolio by tapping into innovation and placing it in the best hands to continuously drive value for customers.Luminex CorporationAcquisitionGermany
Kala Pharmaceuticals$62Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary MPP technology which the company has applied to a corticosteroid, LE, designed for ocular applications, resulting in recently approved INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.BofA Merrill LynchIPOUnited States
Osmotica Pharmaceuticals$61Osmotica has a late?stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: Arbaclofen ER (extended?release) tablets for muscle spasticity in multiple sclerosis patients and RVL?1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.JefferiesIPOUnited States
89Bio$60The funding will be used to advance the company's pipeline of biologic and small molecule drug candidates acquired from Teva. 89Bio's lead candidate for the treatment of NASH is BIO89-100 (formerly TEV-47948). Currently in Phase 1, BIO89-100 is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue that was developed using a proprietary glycopegylation technology to prolong the half-life and optimize the biological activity of native FGF21.OrbiMedSeries A FinancingIsrael
VelosBio$58Arix has built a diverse oncology portfolio that covers a range of different therapeutic modalities including CAR-T, DNA damage response / synthetic lethality, bi-specific antibodies, and targeted viruses. Arix's position in oncology is further strengthened by the investment into VelosBio, extending into ADCs which are meant to only target cancer cells so that healthy cells are less affected.Arix Bioscience plcSeries A FinancingUnited States
Gotham Therapeutics$54Versant created and seeded Gotham based upon the seminal discoveries of co-founder Samie Jaffrey, M.D. Ph.D. in a field within RNA metabolism called epitranscriptomics. The Series A proceeds will allow Gotham to establish clinical proof of concept and to invest broadly in a pipeline of preclinical candidates that have potential to treat diseases intractable to classical approaches.Celgene CorporationSeries B FinancingUnited States
Accera (Cerecin)$50"Rebranding as Cerecin marks the start of a new chapter and the Company's continued commitment to managing some of the world's most devastating brain diseases. The new name, is a combination of the words cerebrum, the Latin word for brain, and medicine, affirming the company's commitment to brain health," explains Charles Stacey, President and CEO of Cerecin.Wilmar Ventures Pte. Ltd. (Wilmar International Limited)InvestmentSingapore
Owlstone Medical$50The funds have been raised to expand commercial opportunities in precision medicine including through the launch of targeted Breath Biopsy kits, and to enable further investment in the technology platform to support the development of additional high value applications.Horizons VenturesInvestmentUnited Kingdom
Pharmeasy$50Pharmeasy provides a technology platform to offer various healthcare services like medicine delivery, medicine refills & reminders, along with teleconsultation.Eight Roads Ventures IndiaSeries C FinancingIndia
Therapix Biosciences Ltd.$48The Transaction is structured at a fixed price of $48M USD ($62.4M CAD), representing approximately 130 million class B subordinate shares of FSD Pharma and nearly 10% of the Company today.FSD PharmaAcquisitionIsrael
XtalPi$46Building on XtalPi’s current momentum and success, the new financing will fuel the development of AI applications for critical steps of drug research and development (R&D), with an immediate focus on algorithmic tools that expand the searchable chemical space in drug discovery.China Life Healthcare FundSeries B FinancingUnited States
PhaseBio Pharmaceuticals$46PhaseBio's lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our proprietary elastin-like polypeptide (ELP) technology, which also serves as the engine for our preclinical pipeline.Needham & CompanyIPOUnited States
Verastem Oncology$45COPIKTRA also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.CSPC Pharmaceutical Group LimitedCommercialization AgreementUnited States
Zhejiang Huahai Pharmaceuticals$43A wholly-owned domestic subsidiary that got some of the money is responsible for drug research and development, manufacturing and the import and export of materials and technologies.Linhai Economic Development ZoneGrantChina
Gamida Cell$40Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.UndisclosedIPOUnited States
Qpex Biopharma$33Qpex is focused on developing new antibiotics to combat the growing threat of global antimicrobial resistance. Qpex acquired the preclinical-stage anti-infective assets of The Medicines Company (MDCO), including proprietary broad spectrum beta-lactamase inhibitor technology.New Enterprise AssociatesSeries A FinancingUnited States
Undisclosed$32Halobetasol foam is a potent corticosteroid used to treat plaque psoriasis. This product received US Food and Drug Administration approval in May 2018 and Mayne Pharma is planning for the commercial launch of this product in early 2019.Mayne Pharma GroupProduct AcquisitionUnited States
Modis Therapeutics$30Modis is advancing its lead experimental therapy, MT1621, as a treatment for thymidine kinase 2 deficiency (TK2d), a rare, genetically defined mitochondrial DNA (mtDNA) depletion disorder.F-Prime Capital PartnersSeries A FinancingUnited States
Glympse Bio$22Glympse’s activity sensors are precisely bioengineered to be transported to the site of disease in patients, directly interrogate the biological activity of the diseased tissue, and emit a signal which can be detected noninvasively from the recipient’s urine.LS Polaris Innovation Fund Series A FinancingUnited States
Xgene Pharma$20Xgene Pharma develops small-molecule drugs for chronic pain, infectious diseases and tumors. Xgene's lead product, a combination of naproxen and pregabalin (Lyrica®) for chronic pain, is in Phase II trials in the US.Ping An VenturesSeries B FinancingChina
Cardialen$17The Cardialen UPT therapy delivers a sequence of low-energy electrical pulses designed to restore abnormally rapid heart rates to a normal rhythm. RiverVest Venture PartnersSeries B FinancingUnited States
Chembio Diagnostics$16Chembio intends to use the net proceeds from the offering to fund its proposed acquisition of opTricon GmbH announced on October 22nd, to support its business growth strategy, including broadening U.S. manufacturing automation and expanding and improving facilities.Craig-Hallum Capital GroupIPOUnited States
Acticor Biotech$15ACT017 is a humanised Antibody Fragment (Fab) which inhibits the action of platelet glycoprotein VI, a novel target of major interest. Evidence of antithrombotic efficacy of ACT017 have been established both ex vivo and in vivo.Newton BioCapitalSeries B FinancingFrance
BioMarin Pharmaceutical$15Medivation, acquired by Pfizer, is responsible for all research, development, regulatory and commercialization activities for all indications globally. In June of this year, the European Medicines Agency accepted the Marketing Application for talazoparib.Medivation (Pfizer) Milestone PaymentsUnited States
Garnet Valley Facility$15The Garnet Valley site will focus on developing small molecule oral drug products, supporting development programs from the preclinical stage through to clinical proof-of-concept.Quotient SciencesManufacturing InvestmentUnited States
Asterias Biotherapeutics$15The site will support Novo Nordisk's increased commitment to develop stem-cell based therapies within type 1 diabetes and other serious chronic diseases.Novo NordiskFacility Lease, License Option AgreementUnited States
RWDC Industries$13Series A2 funds will primarily be used to expand RWDC's PHA (polyhydroxyalkanoate) production capacity in Athens, Georgia (USA), to 2,000 tonnes per year, making it among the world's largest PHA producers by early 2019.Vickers Venture PartnersSeries A2 FinancingSingapore
Chembio Diagnostics$11Chembio’s DPP® HIV 1/2 Assay detects antibodies to HIV-1 and HIV-2 in oral fluid, fingerstick whole blood, venous whole blood, serum or plasma samples, and it provides results in as little as 15 minutes.Bio-Manguinhos CommitmentUnited States
Bayshore Pharmaceuticals$10The acquisition of the majority stake in Bayshore by Ipca Labs’ wholly-owned subsidiary, will enable the company to commercialise its registered generics drug products in the US market through Bayshore. The Company will be able to utilise Bayshore's platform for commercialisation of its registered generics drug products in the United States of America.Ipca Laboratories80% Share CapitalUnited States
NanoView Biosciences$10The company’s proprietary product, the ExoView™ system, was designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision medicineSands Capital VenturesSeries B FinancingUnited States
Glycotest (NetScientific plc)$10NetScientific’s controlling interest will be 51.5% of Glycotest Inc. calculated on a fully-diluted basis following the closing of the Series A Financing. The proceeds will be used to bring Glycotest Inc.’s diagnostic HCC Panel and advance pipeline assets in liver fibrosis and cholangiocarcinoma (bile duct cancer).Shanghai Fosun PharmaSeries A FinancingUnited Kingdom
Princeton University$10The agreement provides $10 million over the next five-years to support healthcare and drug discovery-related technology projects. New Jersey Health FoundationInvestmentUnited States
HiFiBiO Therapeutics$10Kite and HiFiBiO intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies.Kite Pharma (Gilead Sciences)Licensing AgreementHong Kong
Catalent RP Scherer Softgel$7The first phase of investment, completed in August 2018, saw the expansion and upgrade of the facility’s integrated packaging capabilities, and the commissioning of the first of five new softgel encapsulation lines. It is expected that these four new lines will be fully operational by January 2019.Catalent Pharma SolutionsManufacturing InvestmentItaly
Inception-4$6Through this acquisition, Ophthotech gains worldwide development and commercialization rights to Inception 4’s small molecule inhibitors of HtrA1 (high temperature requirement A serine peptidase 1 protein). Ophthotech CorporationAcquisitionUnited States
Weconnect$6The WEconnect app supports patients in their first year of recovery after substance abuse treatment, a crucial time in the rehabilitation process.ServiceNow, Buckingham CapitalSeries A FinancingUnited States
Evotec AG$6The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s unique human induced pluripotent stem cell (“iPSC”) technology platform, which is one of the largest and most sophisticated platforms in the industry.Celgene CorporationExtension of CollaborationGermany
opTricon GmbH$6“The acquisition of opTricon will enable us to further advance our innovative technology development.”Chembio DiagnosticsAcquisitionGermany
Wize Pharma$4Wize Pharma is currently conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH and in the Netherlands for the treatment of DES and Sjögren's.Fordham Financial ManagementPrivate PlacementIsrael
Cell Care Therapeutics$4This round of funding will be used to develop Cell Care’s manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy (DR) and neovascular age-related macular degeneration (wet AMDSyndicate of Individual investorsSeed FinancingUnited States
Raremark$4Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development.Oltre VentureInvestmentUnited Kingdom
Nash Pharmaceuticals$4“Nash Pharma has an exciting story to tell about its technology and its value driven and risk reduced approach to drug development through drug re-purposing.”Breathtec BiomedicalAcquisitionCanada
University College London$4The investment in the UCL Biochemical Engineering's industrial research collaboration program with Pall Biotech is valued at £2.7M ($3.5M) and will engage in multi-level interactions to enable knowledge transfer and address critical industry challenges.Pall BiotechPartnershipUnited States
OmniComm Systems$4The agreement will yield multiple benefits for both companies and provide the clinical research center with the opportunity to further enhance the efficiency of its clinical trials. OmniComm was selected for the partnership based on its EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development.Major Cancer Research CenterPartnershipUnited States
Astrotech Corporation$3Astrotech (NASDAQ: ASTC) is a science and technology development and commercialization company that launches, manages, and builds scalable companies based on innovative technologyThomas B. Pickens IIIPrivate PlacementUnited States
Argonaut Therapeutics$3The Korean drug maker will acquire 25 percent stake in the company to become the second-largest shareholder and will have management rights in the Oxford-based firm, Argonaut Therapeutics is a startup biotech founded at the University of Oxford in 2016. Oxford Sciences Innovationis its largest shareholder.JW Pharmaceutical25% StakeUnited Kingdom
Ionis Pharmaceuticals$3QR-1123 is a first-in-class investigational oligonucleotide (gapmer) that was developed by Ionis Pharmaceuticals using Ionis’ proprietary antisense technology for the treatment of adRP due to the P23H mutation in the RHO gene.ProQR TherapeuticsLicensing AgreementUnited States
Milan Facility$2The 1,350 sq. m (approx. 14,500 sq. ft) facility manufactures intermediates and APIs under GMP conditions. Cambrex currently manufactures over 70 generic APIs which are produced to cGMP standards. The Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant and development and analytical laboratories.Cambrex CorporationManufacturing InvestmentItaly
Oligomerix$2Given that the development of tau pathology correlates well with cognitive impairment, we believe that targeting pathological tau aggregates will be effective using preventive or therapeutic treatment approaches. Dr. Davies, a renowned leader in tau biology, will independently perform these blinded studies.National Institutes of Health, National Institute on AgingGrantUnited States
Sitka Biopharma$2This funding round will enable the company to complete critical GLP toxicology studies and GMP manufacture of clinical drug product. This in turn will allow Sitka and partner Cancer Research UK (CRUK) to complete initial Phase 1 clinical trials of STK-01, Sitka’s lead product for the treatment of bladder cancer.Quark Venture Inc.FinancingCanada
Arcis Biotechnology$2Following its recent development successes in the isolation and preservation of microRNA (miRNA) and oncology biomarkers, Arcis is now looking to invest further in R&D, product development, and to drive international business expansion.Capital CellInvestmentUnited Kingdom
Palashbari Manufacturing Facility$2Notably, Sun Pharma, the number one pharmaceutical company in India and the 5th largest generic drug manufacturing company worldwide, has invested Rs 120 crore to set up this product line which will boost the company's capacity to manufacture liquid vials, injectables, eye drops, tablets. Sun PharmaManufacturing InvestmentIndia
RoslinCT, ReproCell$2The Gov of UK made the investment to collaborate with REPROCELL Europe Ltd (REPROCELL), a UK-based stem cell company, on a project which will develop a faster, more cost-effective method of producing clinical-grade induced pluripotent stem cells (iPSCs).Innovate UKInvestmentUnited Kingdom
Linus Pauling Institute, Helfgott Research Institute$1The NCCIH four-year R01 research project aims to understand how a compound called xanthohumol, from the flowers of the hop plant (Humulus lupulus), may reduce the severity of inflammation in IBD. National Center for Complementary and Integrative Health (NCCIH)GrantUnited States
Rthm Technologies$1Rthm has developed a complete suite of proprietary technology including advanced heart rate tracking and analysis algorithms and comprehensive circadian rhythm mapping techniques. Australis CapitalAcquisitionCanada
NCL Foundation$0.1The NCL Foundation announced today that it is jointly supporting a three-year PhD program in the field of child dementia research with the biotechnology company Evotec AG (Frankfurt Stock Exchange: EVT, MDAX, TecDAX, ISIN: DE0005664809). Under the scientific direction of Dr. med. Guido Hermey (University of Hamburg), the PhD program will take place in the premises and laboratories of Evotec AG.Evotec AG GrantGermany
Alligator Bioscience AB, SARomics Biostructures$0.1ATOR-1017 is an immunostimulatory antibody in development for the treatment of metastatic cancer. It binds to the receptor 4-1BB on tumor-specific T cells and NK cells. The aim is to achieve effective tumor-targeted immune stimulation with minimum side effects. ATOR-1017 is planned to enter clinical studies in cancer patients 2019.VinnovaGrantSweden
Paracelsus Neuroscience$0.1HealthStartNJ funds health-related research, projects or programs of researchers associated with Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology.HealthStartNJ (New Jersey Health Foundation)InvestmentUnited States
AmgrosUndisclosedEffective from today, this first-of-its-kind contract includes current and future CFTR modulator medicines, and means eligible Danish cystic fibrosis (CF) patients will have access to all current medicines as well as future medicines after regulatory approval.Vertex Pharmaceuticals (Europe) LimitedContract AgreementDenmark
Hitachi Chemical Advanced Therapeutics SolutionsUndisclosedNY-ESO is expressed across a variety of tumors including sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer and gastro-intestinal cancers. Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS, formerly PCT Cell Therapy Services, LLC) leverages nearly two decades of experience exclusively focused on the cell therapy industry.GlaxoSmithKlineManufacturing AgreementUnited States
Enesi PharmaUndisclosedThe collaboration is focused on the development and evaluation of a novel solid-dose formulation of a number of PHE’s proprietary vaccine candidates including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever (CCHF) for delivery via Enesi Pharma’s ImplaVax® needle-free technology.Public Health EnglandCollaborationUnited Kingdom
Dr. Reddy's LaboratoriesUndisclosedThe plant and associated facilities focus on manufacturing or packaging amoxicillin-based products, which include a semi-synthetic penicillin.NeopharmaDivestmentUnited States
Lupin LimitedUndisclosedThe partnership between the two companies was initiated in 2011 to expand the promotion and distribution of Lilly's diabetes portfolio in India where Lupin has a large networkEli LillyPartnershipIndia
Dexcom, Glooko and RocheUndisclosedGlobal Head of Roche Diabetes Care Marcel Gmuender added that, "synching Novo Nordisk insulin data with our digital diabetes management solutions like mySugr and Accu-Chek Smart Pix will allow us to enhance quality of care and help create more sustainable healthcare systems."Novo NordiskPartnershipUnited States
Janssen UKUndisclosedSymtuza is a once-daily darunavir-based single-tablet regimen (STR). It is a fixed-dose combination of four active substances – darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF). The funding will enable clinicians across England to routinely prescribe D/C/F/TAF to eligible patients.NHS EnglandFundingUnited Kingdom
LunatusUndisclosedINSYS will supply SUBSYS to Lunatus, and Lunatus will obtain the regulatory approvals and commercialize SUBSYS in the territory.INSYS TherapeuticsLicensing AgreementTurkey
Mayo Clinic Dialysis CenterUndisclosedBaxter International, a global innovator in renal care, and Mayo Clinic today announced a new collaboration to develop a renal care center of excellence in the U.S. The center will serve patients across the continuum of renal care — from chronic kidney disease (CKD) management through transplant — and drive better patient outcomes.Baxter Renal Care ServicesCollaborationUnited States
Promius Pharma (Dr. Reddy’s Laboratories)UndisclosedRon Owens, President of EPI Health, said, “We are very pleased to have completed this agreement with Dr. Reddy’s to acquire Cloderm® Cream in the United States. Cloderm® Cream, and its authorized generic, are widely recognized and time-tested among the dermatology community."EPI HealthDivestmentUnited States
Boston PharmaceuticalsUndisclosedBoston Pharmaceuticals acquired worldwide rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas.NovartisLicensing AgreementUnited States
Boston PharmaceuticalsUndisclosedThe portfolio includes two Phase 2-ready development candidates, one Phase 1-ready development candidate and two undisclosed preclinical programs with identified lead candidates. GlaxoSmithKlineLicensing AgreementUnited States
AXA Hong KongUndisclosedThe newly set up AXA Signature Network will be available in selected plans that will enable its customers to enjoy high-quality medical services, simplified procedures and a revolutionary medical services experience. It may also help to relieve the burden on the public medical system and the pressure on hospital beds.HKSH Medical GroupCollaborationHong Kong
MedherantUndisclosedThe grant will enable the Company to buy equipment and move forward with its plans to extend its pilot scale manufacture of patches formulated with its unique TEPI Patch® technology to GMP manufacture for clinical trials.Innovate UKGrantUnited Kingdom
Evotec AGUndisclosedEvotec will apply its industry-leading discovery technologies to these projects to facilitate rapid and efficient drug discovery and development. For each project, Sanofi has the option to assume development responsibility upon the achievement of pre-agreed milestone criteria.SanofiCollaborationGermany
ClarusUndisclosedThis acquisition launches Blackstone Life Sciences, an industry-leading private investment platform with capabilities to invest across the life-cycle of companies and products within the key life sciences sectors.Blackstone GroupAcquisitionUnited States
ERS GenomicsUndisclosedERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology. Axcelead has all the functions related to non-clinical drug discovery research and is also able to draw on the scientific powerhouse of our personnel with expertise, deep knowledge and experience in a range of therapeutic areas through their previous work at Takeda.AxceleadLicensing AgreementJapan
Vital AccessUndisclosedVwing™ is an implantable device designed to facilitate safe and reliable access to arteriovenous fistulas (AVF) in obese patients suffering from end stage renal disease undergoing hemodialysis. Advent AccessIP AcquisitionUnited States
Ypsomed GroupUndisclosedThe two companies agree to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite digital platform.Royal PhilipsCollaborationUnited Kingdom
OrgenesisUndisclosedHekaBio and Orgenesis will collaborate in the clinical development and commercialization of regeneration and cell and gene therapeutic products in Japan.HekaBio K.K.Licensing AgreementIsrael
Polaris Pharmacy ServicesUndisclosedPolaris will outfit its new pharmacies in Michigan, Minnesota and Florida with MedBank Mini and Tower devices allowing them to reduce labor costs, while improving medication security, availability and delivery for their customers in different states, according to Polaris' Chief Operating Officer Steve Baker.CUBEX® LLC MedBank™ SolutionsPartnershipUnited States
Gilead SciencesUndisclosedThe CAR-T therapy – Axicabtagene ciloleucel, also known as Yescarta – offers new hope for adult patients whose large cell lymphoma has returned or has stopped responding to previous treatment.NHS England, NICECommercial AgreementUnited States
Novartis BiomeUndisclosedThe Novartis Biome connects with external innovators in multiple ways, including issuing challenges through an initiative called the HealthX World Series, proactively scouting for technology, and tapping a large network for referrals.NovartisLaunchUnited Kingdom
Sarepta TherapeuticsUndisclosedThe partnership will provide Sarepta access to additional commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as a manufacturing platform for future gene therapy programs, such as Limb-girdle muscular dystrophy (LGMD).Paragon BioservicesManufacturing PartnershipUnited States
Clinical Trials Laboratory Services (CTLS)UndisclosedCTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.BioIVTAcquisitionUnited States
GLyPharma Therapeutic Inc. UndisclosedThis transformational deal marks Therachon's evolution to a multi-asset rare disease company by adding apraglutide (FE 203799), a next-generation synthetic GLP-2 analog targeting short bowel syndrome (SBS) and other devastating rare G.I. diseases. Therachon AGAcquisitionCanada
ERS Genomics (Summit Pharmaceuticals International Corporation)Undisclosed“Through our agreement with ERS Genomics, we are pleased to be able to enhance the success of our customers' research programs by offering original state-of-the-art CRISPR/Cas9 genome editing services with significantly high knock-in (KI) efficiency,” commented Tsukasa Sugo, CEO of GenAhead. GenAhead Bio is a new spinout biotechnology company focused on genome editing and nucleic acid delivery.GenAhead Bio IncorporatedLicensing AgreementJapan
Jnana Therapeutics UndisclosedThe collaboration will leverage Jnana's proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine's research and development expertise in CNS disorders to advance new medicines.Neurocrine BiosciencesCollaborationUnited States
Iris PharmaUndisclosedKeen Eye is building decision-support and GLP-compliant image analysis solutions to accelerate the development of new therapies with better, faster and accurate analytics. "Through this partnership, we are expecting to contribute to the most challenging image-based assays to better fight eye diseases." -Sylvain Berlemont, Founder & CEO of Keen EyeKeen EyePartnershipFrance
NetsmartUndisclosedCornerstone will leverage the powerful, easy-to-use myUnity Netsmart platform, built specifically for post-acute providers, coupled with its innovative solutions and services that go beyond the traditional EHR.Cornerstone Hospice and Palliative CarePartnershipUnited States
Canalis PharmaceuticalsUndisclosedCanalis is a drug discovery and development company that is using cannabinoids and their NCEs (New Chemical Entities) as small molecule libraries for identifying compounds with human therapeutic activity.Teewinot Life Sciences CorporationLaunchUnited States
DiaSorin S.p.A.UndisclosedMeridian and DiaSorin will begin collaborating on sales and marketing efforts to hospitals and reference laboratories in the U.S. Moreover, Meridian will receive royalties on sales of the LIAISON H. pylori stool antigen test in the U.S. and now also in the UK, in addition to the royalties received under the previous agreement.Meridian Bioscience, IncCollaborationItaly
Vector NeurosciencesUndisclosedMeiraGTx has expanded its portfolio of clinical stage product candidates to include adeno-associated virus encoding glutamic acid decarboxylase (AAV-GAD), a gene therapy product candidate ready for continued Phase 2 clinical development for Parkinson’s disease.MeiraGTx Holdings PlcAcquisitionUnited States
Children’s Hospital of Philadelphia, University of Pennsylvania UndisclosedThe study demonstrated that by reducing levels of a key protein called Foxp3 in immune cells using FANA antisense oligonucleotides (FANA ASOs), a next-generation gene silencing technology, lung cancer survival could be improved. Without Foxp3, Treg cells are unable to perform their immune suppressing function. AUM LifeTechPartnershipUnited States
Cinfa BiotechUndisclosedPelmeg® (originator Neulasta®3) is a pegylated version of granulocyte-colony stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia that works by stimulating the bone marrow to produce more neutrophils, thereby reducing the incidence of infection.Mundipharma International LimitedAcquisitionSpain
Sensei LabsUndisclosedAs an internal communications, collaboration, work orchestration, and learning platform, WE connect provides WE team members with the company information they need to collaborate at scale and thrive in WE’s fast-paced work environment. The platform’s integrated social app, with its dynamic news feed, lets team members share content and interact and connect with peers around the world.WE connect (WE)PartnershipCanada
Digi-Trax CorporationUndisclosedAs partners, WellSky and Digi-Trax are combining efforts to seamlessly integrate cellular therapy compliance labeling and cellular therapy management for clinical laboratory, stem cell transplant, and regenerative medicine. WellSky Biotherapies Lab technology is the preferred cellular laboratory system for Digi-Trax’s HemaTrax®-CT system that offers end-to-end services to safely and efficiently manage donor, clinician, product, and recipient data all in one place with ISBT 128-compliant labelingWellSkyPartnershipAustralia
Urgent Care GroupUndisclosed Urgent Care Group will use DocuTAP companywide and has implemented DocuTAP’s EMR and PM software solutions in their seven MEDcare Urgent Care centers across South Carolina in Anderson, Spartanburg, Columbia, and Charleston.DocuTAPPartnershipUnited States
RaySearch Laboratories ABUndisclosedThe collaboration, that will generate products that will initially be launched in the US market, is expected to enable a more efficient workflow in the process of virtual simulation.Canon Medical Systems CorporationCollaborationSweden
Myriad GeneticsUndisclosedMyriad will provide BRACAnalysis CDx® testing in a Phase 2 study evaluating talazoparib, Pfizer’s investigational polymerase (PARP) inhibitor, for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer.PfizerLaboratory AgreementUnited States
BTG plcUndisclosedCT900 is a targeted therapy that combines targeting folate receptor ? (FR?) and inhibiting thymidylate synthase. The small molecule compound selectively enters cancer cells that over express folate receptor ? (FR?) versus normal tissues and inhibits thymidylate synthase, leading to cell death.Carrick TherapeuticsLicensing AgreementUnited Kingdom
AdynxxUndisclosedAdynxx’s lead product candidate, brivoligide for the reduction of postoperative pain, is intended to provide long-term pain relief and reduced opioid usage with a single administration during surgery.Alliqua BioMedicalMergerUnited States
Dr. Reddy’s Laboratories Ltd.UndisclosedTherapiva is a joint venture between Omnicare Drugs India, a wholly-owned subsidiary of Abu Dhabi based Neopharma LLC, and Laxai Life Sciences. This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and its employees.Therapiva Private LimitedDivestmentIndia
Eagle GenomicsUndisclosedEagle Genomics’ knowledge discovery platform, the e[automateddatascientist], utilizes machine learning and Azure cloud technology to transform data into actionable insights that drive scientific decision making. Microsoft GenomicsPartnershipUnited Kingdom
H-Immune TherapeuticsUndisclosedThe acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. HiFiBiO TherapeuticsAcquisitionChina
Hemogenyx Pharmaceuticals (Immugenyx)UndisclosedImmugenyx will use its advanced hematopoietic chimeras, a new type of humanised mouse with a functional human immune system, to develop a model of lupus.Janssen Research & DevelopmentCollaborationUnited Kingdom
Allele BiotechnologyUndisclosedAllele has engineered novel multi-valent and multi-specific nAbs, originally identified from an immunized llama, to combat cytokine storms. These nAbs have superior therapeutic efficacy over conventional antibody drugs in animal models of sepsis because of their unique structural and functional properties.National Institute of General Medical Sciences of NIHGrantUnited States
Acturum BiovationUndisclosedThe phase II ready molecule (mGluR5 antagonist) could enhance recovery of brain functions after stroke. It was first developed by AstraZeneca and has previously been studied in clinical phase II patients with neuropathic pain.Sinntaxis ABOption AgreementSweden
Verastem OncologyUndisclosedCOPIKTRA is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.Catalent Pharma SolutionsPartnershipUnited States
ERS GenomicsUndisclosedThis non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights.SyngulonLicensing AgreementJapan
IQVIAUndisclosedThis strategic collaboration with a leading innovator in life sciences utilizes IQVIA’s open technology designs and innovative biopharma solutions to enable easy deployment across the globe.Roche (F. Hoffmann-La Roche Ltd)CollaborationUnited States
MeiraGTx Holdings UndisclosedMeiraGTx will use their proprietary riboswitch technology to engineer regulatable gene therapy constructs encoding proprietary gene sequences from Janssen.Janssen PharmaceuticalsCollaborationUnited States
Orion CorporationUndisclosedNovan plans to transfer the technology for the manufacture of SB204, currently in Phase 3 development for the treatment of acne, and intends for Orion to be able to manufacture the drug product, or the finished dosage form of the gel, in accordance with Novan’s established manufacturing processes, in compliance with applicable regulatory guidelines, as appropriate for clinical trials and alongside Novan’s current manufacturing capabilities.NovanManufacturing AgreementFinland
TeleflexUndisclosedTeleflex will harness Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology, which it believes will be disruptive, and is intended to empower clinicians and drive better patient outcomes.Arcis BiotechnologyLicensing AgreementUnited States
Eisai Co., Ltd.UndisclosedEisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country.Eurofarma LaboratoriosLicensing AgreementJapan
Warp Drive BioUndisclosed“The merged R&D portfolio represents a rich pipeline of near- and long-term development opportunities for our R&D team to advance in support of our continuing commitment to translate frontier oncology targets on behalf of cancer patients,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of REVOLUTION Medicines.REVOLUTION MedicinesAcquisitionUnited States
Discovery Life SciencesUndisclosedThe new company will leverage deep scientific expertise and consultative services, combined with the largest repository of more than 10 million research-quality biospecimens—all available and processed for analysis—to accelerate the discovery, research, and development of novel biomarkers, drug candidates, and diagnostics.Conversant Bio, Folio Bio and PhylogenyMergerUnited States
Regenerative Medical TechnologiesUndisclosedThe acquisition includes an allogeneic stem cell product design, intellectual property, access to data and medical records from patients in 13 clinics, and clinical trial methodology for degenerative disc disease (DDD).Predictive Technology GroupAcquisitionChina
Evotec AGUndisclosedEvotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones.Ferring PharmaceuticalsResearch AllianceGermany
OmniComm SystemsUndisclosedThe CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase I clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase I clinics.Global CROPartnershipUnited States
Clinical Network ServicesUndisclosedAs part of the deal, clients can access leading services from both groups including the CNS BioDesk, that provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech’s advanced regional IT infrastructure, to support their clinical research programs.NovotechAcquisitionAustralia
ZappRxUndisclosedZappRx and CureDuchenne’s partnership will drive a more streamlined delivery of life-changing drugs developed from specialty pharmaceuticals emerging to Duchenne patients.CureDuchenneInvestmentUnited States
Herbolea S.r.l.UndisclosedAGMEDICA and HERBOLEA plan to leverage the licensing agreement to deliver distinct and true full-spectrum extracts derived from fresh cannabis and hemp as well as traditional extracts from dried cannabis and hemp, to service the Canadian and German markets. AgMedica Bioscience25% Equity, License Agreement Italy
LabCorpUndisclosedThe collaboration, between Definiens and LabCorp’s Covance drug development business, will enable seamless integration of digital pathology with clinical-trial design and tissue-based testing solutions, resulting in a faster and more rigorous approach to biomarker validation and companion diagnostic co-development.CovanceCollaborationUnited States
MaSTherCell S.A.UndisclosedMaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.Iovance BiotherapeuticsManufacturing Services AgreementBelgium
Berkeley LightsUndisclosedThe collaboration is for the acquisition of Beacon® optofluidic platform through which the companies will leverage the technology to accelerate cell line development with the Selexis SUREtechnology Platform™.Selexis SAAsset AcquisitionUnited States
Genecast BiotechnologyUndisclosedTissue of Origin® (TOO) Test is a microarray-based gene expression test that analyzes a tumor’s genomic information to help identify its origin, which is valuable in classifying metastatic, poorly differentiated, or undifferentiated cancers.Cancer GeneticsCommercial AgreementChina
Microbiome InsightsUndisclosedRebiotix (part of the Ferring Pharmaceuticals Group) and Microbiome Insights, are collaborating to validate one such tool: a proprietary analysis to determine how closely a patient's microbiome resembles that of someone with IBD. Rebiotix (Ferring Pharmaceuticals)CollaborationUnited States
National Center for Tumor Diseases (NCT)UndisclosedThrough this collaboration, Protagen and the NCT Heidelberg will utilize Protagen's Cancer Immunotherapy Array to address challenges such as patients' response to treatment, and checkpoint inhibitors triggered (often severe) immune-related Adverse Events.Protagen AGCollaborationGermany
gA (Grupo Assa)UndisclosedgA was the perfect partner with the right qualifications, and was recommended to LifeScan by Oracle. gA was also LifeScan’s implementation partner for the upgrade to 9.2 release, a pre-requisite for moving to the Cloud, and had in-depth knowledge of LifeScan’s product offering.LifeScanPartnershipArgentina
GenomenonUndisclosedFabric Genomics speeds and scales genomic interpretation by combining the most advanced AI algorithms with automated workflows, while Genomenon’s literature search engine facilitates comprehensive literature review, which is advantageous for accurate interpretation.Fabric GenomicsPartnershipUnited States
ConversaUndisclosedFormativ, which works with physician practices, hospitals and health systems to manage all facets of their patients’ experiences, is using Conversa to enable its clients to communicate easier, faster and in a more significant way with patients.Formativ HealthPartnershipUnited States
Baptist HealthUndisclosedThe new agreement builds upon and deepens an established relationship of more than five years. LabCorp has provided reference testing services as the primary laboratory for Baptist Health’s hospitals and Baptist Health Medical Group physician network.LabCorpCollaborationUnited States
AELIX TherapeuticsUndisclosedThe collaboration will enable the conduct of a clinical study, entitled AELIX-003, to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics’ HTI T-cell vaccine and Gilead´s Toll-Like Receptor 7 (TLR7) agonist vesatolimod in HIV-infected individuals on antiretroviral therapy.Gilead SciencesClinical Research CollaborationSpain
GlycoBac (University of Wyoming)UndisclosedGlycoBac’s development of a proven rhabdovirus-negative (RVN) cell line enables MilliporeSigma to offer the first Sf-9 platform combining a rhabdovirus-free insect cell line with a corresponding, chemically defined cell culture medium.MilliporeSigma (Merck KGaA)Licensing AgreementUnited Kingdom
Inolife R&DUndisclosedInolife developed its Inojex 30 and Nanojex devices to be easy-to-use, safe, pain-free, and more efficient in delivering treatment to patients than is possible with traditional needle-based injections.Empower ClinicsDistribution AgreementCanada
BiomatricaUndisclosedBiomatrica will continue to deploy its capabilities in Exact Sciences’ early cancer screening pipeline as well as with its expanding client base in diagnostics and consumer genomics.Exact SciencesAcquisitionUnited States
Gammaray Private Health ServicesUndisclosedAt the beginning of 2018, Gammaray decided to enter the diagnostics market with liquid biopsy/tissue biopsy/gene signature brands. Gammaray Private Health Services welcomes OncoDNA test brands which are best in class diagnostics to its portfolio as a healthcare provider.OncoDNADistribution AgreementTurkey
Medicines Discovery CatapultUndisclosedFor the first time UK small and medium-sized enterprises (SMEs) will have access to this state-of-the-art bioanalytical technology through research partnerships with the Catapult. The collaboration will also enable AstraZeneca to further unlock the potential of AMI-MS by accessing Medicines Discovery Catapult’s technical expertise.AstraZenecaCollaborationUnited Kingdom
Anaeropharma ScienceUndisclosedThe leading product developed using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S.Chugai PharmaceuticalCollaborationJapan
SpineTheraUndisclosedThe companies believe there is a substantial clinical need for an FDA-approved epidural steroid that demonstrates a long duration of pain relief with a favorable safety profile.Purdue PharmaAcquisitionUnited States
Laurus Labs LimitedUndisclosedDr. Satyanarayana Chava, Founder and CEO, Laurus Labs, commented, "The transfer of TDF ANDA for its use in China enhances our strategic focus to leverage our development and manufacturing capabilities in the markets where we have little presence. Partnering with CASI, in particular, would enable Laurus Labs to monetize its asset in China while building a robust pipeline and commercialize quality drugs in other markets. CASI PharmaceuticalsTransfer AgreementIndia
WuXi BiologicsUndisclosedCANbridge expects to file the first Investigational New Drug (IND) application in a rare disease in China with the lead candidate from this program in 2019. This partnership leverages WuXi Biologics’ drug discovery, development and manufacturing capabilities and CANbridge’s clinical, regulatory and commercial leadership.CANbridge PharmaceuticalsLicensing AgreementChina
AblexisUndisclosedThe non-exclusive license grants Voyager rights to use the AlivaMab Mouse for antibody drug discovery. The AlivaMab Mouse is designed to enable and optimize antibody discovery and development.Voyager TherapeuticsLicensing AgreementUnited States
Pennside Partners Ltd.UndisclosedTwo Labs is a leading pharmaceutical services company that provides a portfolio of product commercialization and lifecycle services to pharmaceutical manufacturers.Two LabsAcquisitionUnited States
NeuRx PharmaceuticalsUndisclosedNT0501 will be developed to address the significant unmet medical needs for the treatment of chronic sialorrhea in adult and pediatric patients with neurological conditions including cerebral palsy, Parkinson’s disease, mental retardation, and amyotrophic lateral sclerosis (ALS). Neos TherapeuticsProduct AcquisitionUnited States
GenoptixUndisclosed“The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach and leaving us better positioned for growth.” said Douglas M. VanOort, NeoGenomics’ Chairman and CEO. NeoGenomicsAcquisitionUnited States
Flex UndisclosedAfter rigorous evaluation, Novo Nordisk selected the medical-grade BrightInsight™ platform from Flex Digital Health to build and operate these solutions and securely manage millions of its smart medical devices and the corresponding data within a regulatory-compliant environment.Novo NordiskPartnershipUnited States
BazeletUndisclosedBazelet will manufacture the products in its recently completed, state of the art, fully GMP compliant manufacturing facility, and expects to begin marketing the products in the first half of 2019.Alvit LCS PharmaLicensing AgreementIsrael
TP TherapeuticsUndisclosedAlmac will develop the NGS diagnostic based on the ArcherDx’s Anchored Multiplex PCR (AMP™) chemistry, with the intent of submitting it for regulatory approval in the United States.Almac Diagnostic ServicesCollaborationUnited States
Novartis AGUndisclosedFLAREX® (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.Eyevance PharmaceuticalsProduct AcquisitionSwitzerland
DelSiTech LtdUndisclosedDelSiTech[TM]Silica Matrix is an advanced, sustained and controlled release delivery technology for administration of injectable, implant and topical eye drop dosage forms.Bill & Melinda Gates FoundationGrantFinland
Merck KGaA-Pfizer allianceUndisclosedThe collaboration aims to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA, Darmstadt, Germany DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors. Daiichi Sankyo Cancer Enterprise (Daiichi Sankyo Group)Clinical Research CollaborationGermany
Brigham and Women's HospitalUndisclosedTo better understand how oncolytic viruses work in human GBM patients, Dr. Lawler is leveraging Mitra's CANscript platform to study their biological mechanisms of action, with the goal of identifying key features involved in response to oncolytic virus therapy.Mitra BiotechCollaborationUnited States
KYAN TherapeuticsUndisclosedUnder the agreement both companies will evaluate the solid tumor responses to various novel combination therapies and dosing seen with Trethera's compound TRE-515.Trethera CorporationCollaborationSingapore
Medicines Development for Global HealthUndisclosedMoxidectin is a macrocyclic lactone anthelmintic medicine that selectively binds to a disease-causing parasite's glutamate-gated chloride ion channels, vital to the function of its nerve and muscle cells.Alcami CorporationCollaborationAustralia
Compact ImagingUndisclosedNovartis will fund Compact Imaging’s development of a low-cost home-based monitor to detect disease progression in advanced cases of age-related macular degeneration (AMD) and diabetic retinopathy (DR).Novartis Pharma AGCollaborationUnited States
Charles River Laboratories InternationalUndisclosedA combination of Distributed Bio’s antibody libraries and Charles River’s extensive drug development expertise will create a unique end-to-end platform for therapeutic antibody discovery and development.Distributed BioPartnershipUnited States
Autism Speaks® Autism Treatment Network (ATN)UndisclosedWhen Quadrant CEO Richard Uhlig learned of the exciting work being conducted by the ATN group, he immediately saw synergies. “Dr. Wink and her colleagues are doing exceptional work on the positive effects of minocycline on children with autism."Quadrant BiosciencesCollaborationUnited States
KariusUndisclosedThe Karius Test is commercially available in the United States, and the partnership with Brazil represents the first expansion into the international market. Specimen samples from local reference laboratories in Brazil will be processed and reported at the CLIA-certified, CAP-accredited Karius laboratory in Redwood City, California. Results will typically be available within 48 hours after receipt of the samples.DasaPartnershipUnited States
IdifarmaUndisclosedIdifarma will handle the full pharmaceutical development of Palobiofarma’s new development candidate, the compound PBF-2897, including drug formulation, development of analytical methods and GMP manufacturing for clinical trials from its EU GMP facility in Pamplona, Spain.PalobiofarmaPartnershipSpain
Chitose GroupUndisclosedIn order to commercialize Mitsui Chemicals’ plant cell culture technology and Chitose Group’s microbiota-activated cultivation technology*, Chitose Group has established “PHYTO Renaissance, Inc.” and “Tierraponica, Inc.” respectively. Chitose Group accepts Mitsui Chemicals employees as a representative of each company and aims to put the businesses of both companies on growth track.Mitsui ChemicalsJoint VentureJapan
NovartisUndisclosedThe companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, Phase 1) and a Ketohexokinase (KHK) Inhibitor (PF-06835919, Phase 2), together with Novartis’s tropifexor, a non-bile acid, Farnesoid X receptor (FXR) agonist.PfizerClinical Development AgreementUnited States
SymphogenUndisclosedThe new collaboration will develop protein analysis workflows to accelerate drug development for biopharmaceutical innovators, biosimilar manufacturers, contract research organizations, and contract development and manufacturing organizations.Thermo Fisher ScientificCollaborationUnited States
Centre For Genetic Health Care (CGHC)UndisclosedMedGenome-CGHC will now have cross functional team comprising of experienced medical geneticists, scientists and bioinformatics etc, who can leverage knowledge and depth on patient scenarios with large amount of curated content for enhanced reporting.MedGenomeAcquisitionIndia
Pharmacy Network ServicesUndisclosed"We are always looking to enhance medication safety and drive operational efficiencies so that we can provide our customers with the best possible service," said Jason Guinn, Pharmacy Network Services Chief Financial Officer. "MedBank is our preferred partner because of its secured, CUBIE Exchange Replenishment Process which allows us to improve our total cost of ownership while at the same time providing the highest accountability for medication management.CUBEX® LLC MedBank™ SolutionsPartnershipUnited States
SeraCare Life SciencesUndisclosedSeraCare is the leading provider of reference materials for clinical genomics applications through their Seraseq brand of highly-multiplexed DNA and RNA reference standards that are helping assay developers and clinical laboratories develop, validate and implement next-generation sequencing (NGS)-based assays more quickly and with higher confidence.AccuRef DiagnosticsPartnershipUnited States
ViewRayUndisclosedThe agreement will allow GenesisCare to advance its vision of precision radiation medicine by contributing to the evidence base for, and delivering, high quality image-guided, adaptive radiotherapy.GenesisCareCollaborationUnited States
Alnylam PharmaceuticalsUndisclosedThe Alnylam Act® program was developed to reduce barriers to genetic testing and counseling in order to help people make informed decisions about their health. As part of the Alnylam Act® program, patients in the U.S. and Canada with a suspected diagnosis or a confirmed family history of primary hyperoxaluria may be eligible to receive Invitae genetic testing at no charge. Invitae will provide results to participating clinicians and their patients in as little as two weeks. Alnylam provides fundInvitae CorporationPartnershipUnited States
Babo BotanicalsUndisclosedThe strategic acquisition of Babo Botanicals will allow Expanscience to strengthen its presence in the baby and family category, with the addition of a business and brand that are complementary to its own Mustela brand, in terms of product lines, customers and expertise, particularly in the natural skin care and mineral-based sun care categories.Laboratoires ExpanscienceAcquisitionUnited States
Octane BiotechUndisclosedFollowing an intensive joint-development program, the CocoonTM system now incorporates the majority of unit operations needed for scalable end-to-end manufacturing of cell therapies including Mesenchymal stem cells (MSC) and Chimeric Antigen Receptor T cells (CAR-T cells).Lonza CDMOMajority StakeCanada
TransgeneUndisclosedNEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.NEC CorporationMemorandum of Understanding (MoU)France
CaresyntaxUndisclosedMC Healthcare, providing an integrated healthcare supply chain platform for hospitals, is serving about 250+ facilities in Japan. MC HealthcarePartnershipGermany
MeiraGTx HoldingsUndisclosedMeiraGTx will receive worldwide rights to adeno-associated virus vector mediated gene delivery of aquaporin-1, designated AAV-AQP1, for Sjögren’s syndrome patients with associated xerostomia (dry mouth) or xerophthalmia (dry eyes). National Institute of Dental and Craniofacial Research (NIDCR)Licensing AgreementUnited States
University of Pennsylvania, University of Florida Research FoundationUndisclosedBest vitelliform macular dystrophy affects individuals in both eyes and is an orphan inherited degenerative retinal disease caused by mutations in the BEST1 gene. Ophthotech will sponsor research at Penn, facilitated by the Penn Center for Innovation (PCI), and the University of Florida to conduct preclinical and natural history studies of Best disease.Ophthotech CorporationOption AgreementUnited States